Back to top

healthcare: Archive

Urmimala Biswas

Investing in the Age of Longevity: Silver Economy Stocks in Focus

AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.

ABTPositive Net Change AMGNPositive Net Change MDTNegative Net Change SYKPositive Net Change DXCMPositive Net Change ABBVPositive Net Change

Urmimala Biswas

Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now?

BFLY trades at distressed levels with analyst targets signaling sharp upside, while TEM's premium valuation tempers its appeal.

AZNPositive Net Change NVDANegative Net Change BFLYNegative Net Change TEMPositive Net Change

Urmimala Biswas

Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold?

Tempus AI's soaring Q2 revenues, margin gains and near-EBITDA breakeven position it as a fast-rising force in precision medicine.

IRTCNegative Net Change SOPHNegative Net Change TEMPositive Net Change

Kaibalya Pravo Dey

When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline

ELV's 20% YTD slump reflects shrinking memberships, rising costs and deepening analyst pessimism despite long-term growth levers.

UNHPositive Net Change CNCPositive Net Change ELVPositive Net Change

Urmimala Biswas

Is CVS a Smart Buy Now on Strong Q2, Low Valuation & Long-Term Upside?

CVS appears well-poised on strong Q2 revenue growth, raised full-year guidance and momentum in key healthcare segments.

UNHPositive Net Change CVSPositive Net Change HLFNegative Net Change

Kaibalya Pravo Dey

UnitedHealth Crashing After Q2 Shock: Should You Panic or Pounce?

UNH plunges 12.9% after weak Q2 and slashing 2025 EPS guidance, sparking fears of deeper structural issues ahead.

UNHPositive Net Change MOHPositive Net Change CNCPositive Net Change

Urmimala Biswas

Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?

TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.

AZNPositive Net Change TXGPositive Net Change SOPHNegative Net Change TEMPositive Net Change

Urmimala Biswas

Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?

Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.

AZNPositive Net Change NVOPositive Net Change NVDANegative Net Change TEMPositive Net Change

Urmimala Biswas

CVS or UnitedHealth: Which Stock Is a Better Buy Ahead of Q2 Earnings?

CVS shows resilience with stable insurance margins and capital discipline, while UNH faces cost headwinds and a sharp earnings cut.

UNHPositive Net Change CVSPositive Net Change

Kaibalya Pravo Dey

UnitedHealthcare Pressure Builds: Trouble Ahead for UNH's Q2 Earnings?

UNH braces for a steep Q2 profit drop as soaring medical costs and DOJ scrutiny shake investor confidence.

UNHPositive Net Change HUMPositive Net Change MOHPositive Net Change